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Abstract
The bulk of familial breast cancer risk (,70%) cannot be explained by mutations in the known predisposition genes,
primarily BRCA1 and BRCA2. Underlying genetic heterogeneity in these cases is the probable explanation for the failure of all
attempts to identify further high-risk alleles. While exome sequencing of non-BRCA1/2 breast cancer cases is a promising
strategy to detect new high-risk genes, rational approaches to the rigorous pre-selection of cases are needed to reduce
heterogeneity. We selected six families in which the tumours of multiple cases showed a specific genomic profile on array
comparative genomic hybridization (aCGH). Linkage analysis in these families revealed a region on chromosome 4 with a
LOD score of 2.49 under homogeneity. We then analysed the germline DNA of two patients from each family using exome
sequencing. Initially focusing on the linkage region, no potentially pathogenic variants could be identified in more than one
family. Variants outside the linkage region were then analysed, and we detected multiple possibly pathogenic variants in
genes that encode DNA integrity maintenance proteins. However, further analysis led to the rejection of all variants due to
poor co-segregation or a relatively high allele frequency in a control population. We concluded that using CGH results to
focus on a sub-set of families for sequencing analysis did not enable us to identify a common genetic change responsible
for the aggregation of breast cancer in these families. Our data also support the emerging view that non-BRCA1/2
hereditary breast cancer families have a very heterogeneous genetic basis.
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Introduction
The genetic landscape of breast cancer susceptibility known to
date is constituted by more than 30 gene loci. Mutations in some
of these, like BRCA1 and BRCA2, are extremely rare, but confer
high risks to breast cancer, others are common but only confer a
minor increase in risk. However, jointly these alleles explain less
than 30% of the familial breast cancer risk [1–3]. When
considering families with multiple cases of early-onset breast
cancer in which mutations in the known high-risk genes have been
excluded (hereafter: ‘‘BRCAX’’ families), an unknown, rare,
highly penetrant allele would appear to be the most parsimonious
genetic explanation. However, linkage studies have not discovered
any major breast cancer susceptibility gene since the identification
of BRCA1 and BRCA2. This suggests that these high-risk alleles are
too rare to be detected by linkage studies in unselected BRCAX
families.
Therefore, an important factor determining the success of a
genome-wide search for linkage in a set of BRCAX families is the
extent of underlying genetic heterogeneity. Simulation studies
have shown that study power drops sharply if mutations in the
sought-after new gene explain ,30% of the investigated families.
Selecting families based on a shared phenotype might lead to a
genetically more homogeneous group of families, which are more
likely to share variants in the same gene. A shared phenotype
might be defined by the presence of certain cancer types in the
family. For example, linkage analysis of non-BRCA1 breast cancer
families with a case of male breast cancer, led to the discovery of
the BRCA2 locus [4]. Also, certain histopathological features of
tumours might be used to identify subgroups. It has been shown
that breast tumours from BRCA1 and BRCA2 mutation carriers
show specific genomic profiles as determined by comparative
genomic hybridization (CGH) [5–10].
We recently described a specific array comparative genomic
hybridization (aCGH) profile in a subgroup of BRCAX breast
tumours [11]. This aCGH-profile is characterized by a gain of
almost whole chromosome 22, in combination with some other
specific changes, and was observed to be present in multiple breast
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cancer cases contained within six of the 27 analyzed BRCAX
families. We hypothesized that these six families might have
mutations in the same high-risk breast cancer gene. Here we
present linkage analysis of these six families as well as exome
sequencing of two family-members from each.
Methods
Patients
Previously, we determined the aCGH profiles of 58 breast
tumours from 27 BRCAx families. A detailed description of the
original selection criteria of the BRCAx families is given in
Didraga et al. [11]. We selected six of these families in which the
tumours of multiple cases showed the 22-gain-like profile. The
pedigrees of these families are depicted in Figure 1a-f. The
occurrence of cancer was assessed through the index case and
whenever possible verified with pathology reports. The number of
breast cancer cases per family ranged from five to eleven, with a
mean age of onset of 54 years. No male breast cancer cases and no
ovarian cancer cases were reported. In total 46 breast tumours
were diagnosed in these families, of which four were second
primary tumours. One breast cancer case developed a kidney
tumour and another breast cancer case was diagnosed with colon
cancer. Other cancers that occurred in these families were liver
cancer (n = 3), stomach/oesophagus cancer (n = 3), colon cancer
(n = 2), melanoma (n= 1), cervical cancer (n = 1), prostate cancer
(n = 1) and two cancers of unknown type. All participants provided
written informed consent and approval of the medical ethical
committee at the Leiden University Medical Centre was obtained.
Linkage Analysis
The six selected families are part of a larger cohort of = 55
families, which were genotyped before by Oldenburg et al [12] for
a genome-wide linkage analysis study. In brief, all individuals from
whom DNA was available were genotyped using the Linkage
Mapping Set MD10 from Applied Biosystems consisting of 400
markers which results in a 10 centimorgan resolution. Genotypes
were called automatically using Genemapper software(Applied
Biosystems) and checked manually. Allele frequencies were
calculated based on one randomly chosen individual from each
family. The UNKNOWN program of the LINKAGE package
[13] was used to check for Mendelian errors. If after manual
reassessment of the raw data Mendelian errors could not be solved
these genotypes were changed to ‘‘untyped’’ (i.e., ‘‘0 0’’). We
performed a multipoint linkage analysis using Genehunter
software (version 2.1 B) [14]. We assumed a model with a
dominant susceptibility allele with an allele frequency of 0.003.
Breast cancer risk at age 80 for carriers of the risk allele was
assumed to be 0.85. For non-carriers we assumed a risk of 0.096.
Risks were modelled in seven age categories as described by
Easton et al. [15]. Under the assumption of homogeneity, the
LOD scores of the six families linked to the 22-gain profile were
added up. To define the limits of a linkage region we took the
maximum LOD score minus one as a cut-off.
Exome Sequencing
Genomic DNA was extracted from peripheral blood using
standard protocols. Samples were prepared according to the
manufacturers protocol (SureSelect All Exon (v1), Agilent Tech-
nologies) with some minor adjustments. In brief, for each
individual 5 mg DNA was fragmented using adaptive focused
acoustics (Covaris S-series single tube) in order to get fragments of
200–300 bp. Primer oligonucleotides for paired-end sequencing
(Illumina) were ligated to both ends of the fragment. Of each
sample 500 ng was then hybridized with 2.5 ml SureSelect Oligo
Capture Library for 20 hours. After multiple washing steps, the
captured DNA was amplified in order to get sufficient DNA for the
sequencing experiment. Paired-end flow cells were then prepared
on a cluster station according to the manufactures protocol
(Illumina), using one lane per sample. Sequencing was the
performed on a Genome Analyzer IIx (Illumina) with a paired-
end module, generating 75 base pair reads.
Data Analysis
Alignment of the reads was done using the GAPPSv3 pipeline.
Before alignment raw reads were filtered for adapter sequences
and low quality bases using the FastxToolkit [16]. Alignment to
the human reference genome (hg19, GRCh37) was done using
Stampy [17] which integrates BWA [18] for bulk alignment and its
own algorithm for complex regions. For detailed settings see Table
S1. Variants were called with VarScan [19]. Filter settings applied
a minimum coverage of 10 times at the variant position, and a
variant allele frequency of at least 30% of the reads. In the region
of the linkage peak we increased the sensitivity by calling variants if
the variant allele was supported by at least 15% of the reads.
Annotation of the variants was done using SeattleSeq (version
7.01, [20]). Assuming that causal variants are rare, we removed all
variants with an allele frequency .1% in either HapMap [21],
1000 genomes (phase 1) [22], exome variant server (v.0.0.11,
ESP5400, [23]) or our in-house variant database (containing 298
non-cancer exomes). In addition, variants that were found in a
homozygous state in at least one of the twelve individuals were
removed.
Sanger sequencing and melting curve analysis (MCA)
Validation of variants was done using PCR following standard
protocols, followed by Sanger sequencing on an ABI3730XL
sequencer. To assess variant frequencies in familial breast cancer
cases and controls, high resolution melting curve analysis was
performed. Non-BRCA1/2 familial breast cancer cases (n = 531)
were obtained from the clinical genetics centre Leiden and healthy
controls (n = 458) were obtained from the Dutch blood bank,
Sanquin. PCR was performed in a 1:10:10 forward primer: reverse
primer: probe ratio in the presence of LC green (Idaho
Technology Inc.). Melting curves were assessed on a LightScanner
(Idaho Technology Inc.) for temperatures between 50uC and 90uC
and analyzed with Call-IT software (Idaho Technology Inc.). All
primer and probe sequences are available upon request.
Results
We previously analysed the breast tumours of 58 patients from
27 BRCAX families using aCGH [11]. Hierarchical clustering
identified several subgroups of BRCAX tumours, one of which
was characterized by a gain of chromosome 22. Remarkably, in 6
families, tumours from multiple patients displayed this chromo-
some 22 gain profile (Figure 1). Linkage analysis under homoge-
neity revealed a linkage peak with a LOD score of 2.49 on
chromosome 4 in these six families (Figure 2 and Figure S1). The
next highest linkage peak was 1.04 at 10q and no other linkage
peaks with a LOD score greater than 1.0 were detected.
A 25-Mb candidate region (chr4:40.000.000-65.000.000) was
defined as the region showing a LOD score greater than the peak
LOD score minus one. Two individuals per family were selected
for exome sequencing, usually at least second-degree relatives
(figure 1). (Details on coverage of the individual exomes can be
found in Figure S2 and S3.) This revealed on average 499 variants
in the candidate region that were shared by both individuals of a
Exome Sequencing of BRCAx Cases Selected with aCGH
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family. After removing intergenic and non-conserved variants in
non-coding regions, five variants remained (Table 1). However,
none of the genes carrying these variants were found to do so in
two or more families. Hence mutations in a single gene are less
likely to explain the linkage result. We then considered the
possibility that two or more genes in the chromosome 4 region
each fortuitously carries a high-risk mutation in one of the six
families. Of the detected variants, three synonymous variants in
three genes (FRYL, AASDH, PPAT) were not further examined,
because these variants are unlikely to affect protein function. A
missense variant in REST and a well-conserved 39UTR variant in
LNX1 were validated by Sanger sequencing. The LNX1 variant
was present in five of eight cases in family RUL070. The missense
variant in REST was detected in six out of seven cases in family
RUL079, however Grantham and conservation scores for this
variant were low (Grantham=45, Phastcons = 0.00,
GERP=23.56) and Polyphen [24] predicts it to be benign.
Finally, we examined the possibility that the six families shared
variants in a gene outside the linkage peak region (whole exome).
We first focused on variants that were likely to result in a truncated
protein (gained stop-codon, frameshift and splice-site variants). In
the six families we found in total 49 different, rare protein-
truncating variants in 48 genes. A number of genes showed a
protein-truncating variant shared by several families. However, all
these variants were present in regions whose sequences showed
large similarities with regions elsewhere in the genome. When
Figure 1. Pedigrees of the families in which multiple tumours showed the ‘‘22-gain-like’’ aCGH profile. Individuals affected with breast
cancer are represented by a filled square or circle. Individuals affected by another type of cancer are represented by a square or circle with a vertical
black stripe. Below the age at diagnosis and type of cancer can be found: B stands for breast cancer, Li or liver cancer, S for stomach cancer, Oes for
oesophagus cancer, C for colon cancer, M for melanoma, Cvx for Cervix cancer, K for kidney cancer, P for prostate cancer and U for type of cancer
unknown. Arrows point at the individuals at whose DNA was used for exome sequence. Individuals with tumours with and without the ‘‘22-gain-like
profile’’ are represented by ‘‘22+’’and ‘‘222’’.
doi:10.1371/journal.pone.0055734.g001
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examining the unprocessed sequence-reads of the families in which
the variants were not called, in most instances the variant could be
detected, but in fewer reads than the required threshold of 30%.
Thus, we considered all these variants to be false-positive findings
resulting from sequence read-mapping errors. Indeed, the only
one of these variants that we followed up by Sanger sequencing
was a splice-site mutation in FANCD2. FANCD2 is a Fanconi
Anaemia gene and therefore a candidate breast cancer gene.
However, upon re-sequencing, this variant was not present in
FANCD2, but in a region with a similar sequence elsewhere on
chromosome 3 near EMC3 (data not shown).
After removing the variants resulting from read-mapping errors,
21 truncating variants remained (see table S2). All were present in
only one of the six families. Of these variants a frameshift
mutation, c.811delT, in HAUS3 was potentially interesting,
because HAUS3 has been reported to be somatically mutated in
a lobular breast tumour [18]. Sanger sequencing showed that five
out of seven breast cancer patients in RUL079 had this deletion.
High resolution melting curve analysis of this specific variant did
not reveal any additional carriers among 531 familial breast
cancer cases. However, three individuals in a group of 458 healthy
controls were found to carry the c.811delT, dismissing it as a high-
risk breast cancer allele.
We also took into account possibly damaging missense variants.
This was defined as missense variants with either a Grantham
score .100, a GERP conservation score .3, a PhastCons
conservation score .0.7 or a ‘‘probably damaging’’ PolyPhen2
prediction. Due to the large number of variants remaining
(n = 657), following up all variants with Sanger sequencing was
deemed impractical. We therefore selected variants with a function
in DNA integrity maintenance, because the majority of breast
cancer susceptibility genes identified to date have a function in this
pathway (table 2). Again, no genes were found to have a variant in
more than one family. However, some individual families showed
possibly damaging variants in genes (n = 8) involved DNA damage
repair or chromosome segregation, shared by both assayed
individuals. One of these variants, present in RBMX, could not
be validated. However, a variant in HLTF, p.S378T, was present
in five out of five cases of family NIJM008. This variant was
selected because of a high GERP conservation score (3.15). The
PhastCons conservations score, however, was only 0.21 and this
variant was predicted to be benign by Polyphen2. Sanger
sequencing showed that the remaining six variants, in CASC5,
CUL9,MUTYH, SMC6, TTK and XRCC2, had a poor or moderate
co-segregation with disease (Figure S4). Interestingly, the variant in
XRCC2 was also detected in an Australian family and therefore
further analysed in an international mutation scanning effort [25].
A significant association between rare XRCC2 variants and
familial breast cancer was reported. However, a large validation
study was not able to confirm this association [26].
Discussion
The landscape of genetic risk factors for breast cancer is known
to be diverse, ranging from rare high-risk alleles, like BRCA1 and
BRCA2, to common polymorphisms that only confer a minor
breast cancer risk increase. The large proportion of familial breast
cancer cases that is not explained by the genetic risk factors known
Figure 2. Linkage on chromosome 4 for the families in which multiple tumours showed the ‘‘22-gain-like’’ aCGH profile. The LOD-
score was calculated under the assumption of homogeneity. The dashed lines indicate the maximum LOD-score -1interval. The X-axis shows the
position on chromosome 4 in centimorgan and the markers with a LOD score .0 are indicated. The highest LOD score of 2.49 was located at marker
D4S405.
doi:10.1371/journal.pone.0055734.g002
Table 1. Well conserved or coding variants in the linkage region on chromosome 4.
Variant Gene Family Effect rs-number PhastCons1 GERP1
Chr4:g.48545947T.C FRYL RUL070 Synonymous - 1.00 1.33
Chr4:g.54327036_54327037insATT LNX1 RUL070 39 UTR 57366823 0.97 4.56
Chr4:g.57248742A.C AASDH RUL070 Synonymous 146114987 1.00 20.43
Chr4:g.57261623G.A PPAT RUL070 Synonymous - 0.22 25.98
Chr4:g.57797037G.T REST RUL079 Missense2 138787075 0.00 23.56
1Phastcons and GERP are both regional conservation algorithms ranging from 0 to 1 and 212.3 to 6.17 respectively (1 and 6.17 being most conserved).
2Grantham=45, PolyPhen prediction = Benign.
doi:10.1371/journal.pone.0055734.t001
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to date are thought to have a very heterogeneous basis [1–3]. Both
segregation analysis [27–29] and the fact that no major high-risk
breast cancer genes have been identified since BRCA2 suggest that
additional high-risk alleles are much rarer than mutations in
BRCA1 and BRCA2. Exome sequencing might be a very useful tool
to identify these very rare high-risk alleles. However, finding novel
disease alleles among thousands of not-pathogenic variants might
be more complex in a common and genetically heterogeneous
disease like breast cancer, than in the rare Mendelian phenotypes
in which exome sequencing has been very successful to date [30].
Therefore selecting a genetically more homogeneous patient
subgroup seems crucial.
We hypothesized that by selecting BRCAX families with a
similar phenotype, we would enrich our study population for
families with germline mutations in the same gene. In this study six
BRCAX families in which the majority of tumours show a
previously identified aCGH profile [11] were selected. Linkage
analysis in these families showed a peak on chromosome 4, which
suggested that these families might share a genetic aetiology.
Massively parallel sequencing after whole-exome capture was
performed on two individuals per family, but no genes were
identified in which more than one family showed a likely
pathogenic variant after assessing the predicted effect on the
protein and co-segregation. Nonetheless, we did detect multiple
possibly pathogenic variants in genes that encode for DNA
integrity maintenance proteins outside the linkage peak region.
However, none remained as likely causes of familial clustering of
breast cancer because of poor co-segregation or relative high
frequency of the specific variant in a control population.
It is important to realize that, by enriching our samples for the
coding regions of the DNA, we might have missed relevant
variants in the promoter, deep intronic regions affecting splicing or
in regulatory regions further away from the causal gene. However,
such mutations seem to represent only a minority of the mutation
mechanisms in the known disease-related genes, as recorded in
OMIM and other public databases [31]. It seems less likely
therefore, that all families in our study population were due to such
mutations. In addition, variants outside the coding regions are
much harder to interpret functionally, and a whole-genome
sequencing approach would have resulted in thousands of variants
of uncertain clinical significance.
Multiple studies have shown that aCGH classifiers can be built
to distinguish BRCA1 and BRCA2 tumours from sporadic tumours
and each other [5–10]. These studies suggest that tumours of
patients with mutations in the same gene also share a somatic
genetic aetiology. Alvarez [32] and colleagues found that part of
the BRCAX tumours showed aCGH profiles similar to those of
BRCA1 tumours. A large proportion of these tumours turned out
to have hypermethylation of BRCA1. Some studies that performed
aCGH profiling on BRCAX tumours find similarities with profiles
of BRCA2 tumours [33,34], suggesting that either a cause of
BRCA2 inactivation in these tumours has yet to be detected or that
inactivation of a number of genes can lead to a similar aCGH
profile. It might be that patients with the 22-gain profile do not
share mutations in the same gene, but in the same pathway. In
order to detect an enrichment of deleterious variants in a specific
pathway, a large number of familial patients with 22-gain tumours
will need to be sequenced, preferably in conjunction with gene
expression profiling of tumours; however it will be challenging to
collect sufficient numbers samples for such an effort.
Another possibility is that patients with a 22-gain tumour have
mutations in a moderate risk gene.
Muranen et al. [35] have shown that specific aCGH features
occur significantly more often in tumours of patients with a
CHEK2*1100delC mutation. This suggests that also moderate risk
germline mutations can lead to a homogenous phenotype. By only
assessing variants that are shared by both family members and
discarding variants that show poor co-segregation, we may have
missed variants in a moderate risk gene. In addition, moderate risk
variants might have an allele frequency of more than 1% as has
been shown to be true for the CHEK2*1100delC mutation in some
populations [36]. However without using these selection criteria, it
would not have been possible to limit possibly interesting variants
to a number that is manageable to follow-up. Therefore a study
design that includes exome sequencing in a very limited number of
familial cases is underpowered to detect moderate risk variants.
A good balance between stringent selection criteria (to limit the
number of variants for follow-up) and not excluding too many
potentially interesting variants is difficult to find. An excess of rare
genetic variants due to recent explosive growth of the human
population has been observed [37,38]. This makes it difficult to
interpret the effect of a very rare variant on breast cancer risk
Table 2. Possibly damaging or well conserved variants in genes encoding proteins involved in DNA integrity maintaince.
Gene Variant GranthamGERP1 PhastCons1PolyPhen2 Function
CASC5 p.I26L 5 4.53 0.999 Probably damaging Spindle-assembly checkpoint signaling and chromosome
alignment
CUL9 p.S2328F 155 5.03 0.989 Possibly damaging Regulates the subcellular localization of p53 and subsequent
function
HLTF p.S378T 58 3.15 0.208 Benign Error-free postreplication repair of damaged DNA
MUTYH p.I223V 29 5.43 1 Benign Oxidative DNA damage repair
RBMX p.Y357H 83 5.66 1 Probably damaging Regulation of programmed cell death in breast cancer and
homologous recombination
SMC6 p.R403W 101 2.65 0.998 Probably damaging DNA damage repair via homologous recombination
TTK p.R185W 101 4.04 0.004 Probably damaging Chromosome alignment, centrosome duplication and critical
mitotic checkpoint
XRCC2 p.R91W 101 4.48 0.742 Probably damaging DNA damage repair via homologous recombination
Variants were selected if either of these criteria was met: Grantham score.100, GERP conservation score.3, PhastCons conservation score.0.7, or a ‘‘Probably
damaging’’ Polyphen2 prediction.
1Phastcons and GERP are both regional conservation algorithms ranging from 0 to 1 and 212.3 to 6.17 respectively (1 and 6.17 being most conserved).
doi:10.1371/journal.pone.0055734.t002
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outside the family it was originally detected in. For example, the
missense variant we detected in XRCC2 was also found in an
Australian BRCAX family [25]. Whereas we had initially
dismissed this variant because it did not show convincing co-
segregation with disease, the fact that Park et al. had also found a
protein-truncation variant in XRCC2, prompted a mutation scan
of a large population of familial breast cancer cases and controls.
This detected a significant association between familial breast
cancer and XRCC2 [25]. However, an even larger international
validation of these results was unable to confirm this association
[26]. This leaves the possibility that some very rare XRCC2 alleles
are true breast cancer susceptibility alleles, but conferring only
moderate risks, which would require huge association studies to
demonstrate. This example emphasizes the importance of
international collaboration and sharing of data, both in the
variant selection and in the validation phase.
In conclusion, we did not find evidence for mutations in a rare
high-risk gene in a subgroup of BRCAX cases defined by an
aCGH profile. Although, we cannot rule out that these families
have mutations in genes belonging to the same pathway or in a
non-coding region. Exome sequencing efforts in large cohorts of
BRCAX cases are needed to definitively unravel the genetic basis
underlying the aetiology of unexplained familial clustering of
breast cancer and its link with tumour characteristics.
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